ACB reports C$43.3 million in international medical cannabis revenue for 1Q FY27, offsetting Canadian pricing pressures and supporting growth outlook.
Aurora Cannabis Inc. (ACB) reported a 17% year-over-year increase in international medical cannabis revenue to C$43.3 million in the first quarter of fiscal 2027. The growth underscores the company’s expanding footprint in global medical markets despite challenges in its domestic operations.
Total net revenue for the quarter ended June 30, 2026, fell 9% year-over-year to C$67.6 million, down from C$74.1 million in the prior-year period. The decline was driven by a 30% reduction in Canadian federal medical reimbursement rates and the phased exit from the consumer cannabis segment. Adjusted gross margin reached 58%, aligning with the high end of FY27 guidance.
Management highlighted momentum in key markets, including Safari and Germany, with a three-year EU-GMP certification bolstering internal supply for high-margin international sales. The company expects sequential revenue and adjusted EBITDA growth in 2Q, with Street estimates projecting FY28 expansion and positive free cash flow.